Risk of prolonged sedation with the use of chlordiazepoxide in alcohol withdrawal treatment
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
SummaryThe use of chlordiazepoxide in the treatment of alcohol withdrawal symptoms poses a risk of prolonged sedation with the need of weeks lasting antidote treatment, and extended hospitalization due to active metabolites with very long half-lives.We present four case stories to elucidate this issue. One patient received 800 mg chlordiazepoxide and was treated with flumazenil for 42 days. Another patient was treated with 100 mg chlordiazepoxide. 5 days after administration of chlordiazepoxide, concentrations of chlordiazepoxide and its active metabolite demoxepam, were within therapeutic range, the patient was treated with flumazenil for 6 days. He died after palliative care.The great individual variation in the clinical effect of chlordiazepoxide depends on the activity of the CYP P450 system, especially CYP3A4/A5 and CYPS2C19, which can be impaired in cirrhotic and elderly patients.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Adverse Drug Reaction Bulletin |
Vol/bind | 340 |
Udgave nummer | 1 |
Sider (fra-til) | 1319-1322 |
Antal sider | 4 |
ISSN | 0044-6394 |
DOI | |
Status | Udgivet - 1 jun. 2023 |
Bibliografisk note
Publisher Copyright:
© 2023 Lippincott Williams and Wilkins. All rights reserved.
ID: 368254628